| Candidate drugs against SARS-CoV-2 and COVID-19 DL McKee, A Sternberg, U Stange, S Laufer, C Naujokat Pharmacological research 157, 104859, 2020 | 605 | 2020 |
| Emerging and re-emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology M Gehringer, SA Laufer Journal of medicinal chemistry 62 (12), 5673-5724, 2018 | 509 | 2018 |
| Determination of the wound healing effect of Calendula extracts using the scratch assay with 3T3 fibroblasts M Fronza, B Heinzmann, M Hamburger, S Laufer, I Merfort Journal of ethnopharmacology 126 (3), 463-467, 2009 | 418 | 2009 |
| In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer R Rudalska, D Dauch, T Longerich, K McJunkin, T Wuestefeld, TW Kang, ... Nature medicine 20 (10), 1138-1146, 2014 | 302 | 2014 |
| Spinal inhibition of p38 MAP kinase reduces inflammatory and neuropathic pain in male but not female mice: Sex-dependent microglial signaling in the spinal cord S Taves, T Berta, DL Liu, S Gan, G Chen, YH Kim, T Van de Ven, S Laufer, ... Brain, behavior, and immunity 55, 70-81, 2016 | 296 | 2016 |
| A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer D Dauch, R Rudalska, G Cossa, JC Nault, TW Kang, T Wuestefeld, ... Nature medicine 22 (7), 744-753, 2016 | 272 | 2016 |
| Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept F Celotti, S Laufer Pharmacological Research 43 (5), 429-436, 2001 | 236 | 2001 |
| Tetrasubstituted imidazole inhibitors of cytokine release: probing substituents in the N-1 position SA Laufer, W Zimmermann, KJ Ruff Journal of medicinal chemistry 47 (25), 6311-6325, 2004 | 223 | 2004 |
| Biological studies on Brazilian plants used in wound healing C Schmidt, M Fronza, M Goettert, F Geller, S Luik, EMM Flores, ... Journal of ethnopharmacology 122 (3), 523-532, 2009 | 206 | 2009 |
| The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and … JP Pelletier, C Boileau, J Brunet, M Boily, D Lajeunesse, P Reboul, ... Bone 34 (3), 527-538, 2004 | 206 | 2004 |
| Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1 A Koeberle, U Siemoneit, U Bühring, H Northoff, S Laufer, W Albrecht, ... Journal of Pharmacology and Experimental Therapeutics 326 (3), 975-982, 2008 | 197 | 2008 |
| The cysteinome of protein kinases as a target in drug development A Chaikuad, P Koch, SA Laufer, S Knapp Angewandte Chemie International Edition 57 (16), 4372-4385, 2018 | 191 | 2018 |
| Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial … JP Raynauld, J Martel-Pelletier, P Bias, S Laufer, B Haraoui, D Choquette, ... Annals of the rheumatic diseases 68 (6), 938-947, 2009 | 183 | 2009 |
| New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase C Peifer, G Wagner, S Laufer Current topics in medicinal chemistry 6 (2), 113-149, 2006 | 178 | 2006 |
| Structural approaches to explain the selectivity of COX-2 inhibitors: is there a common pharmacophore? G Dannhardt, S Laufer Current Medicinal Chemistry 7 (11), 1101-1112, 2000 | 178 | 2000 |
| PGE2 in the regulation of programmed erythrocyte death PA Lang, DS Kempe, S Myssina, V Tanneur, C Birka, S Laufer, F Lang, ... Cell Death & Differentiation 12 (5), 415-428, 2005 | 177 | 2005 |
| Studies on the anti-inflammatory activity of phytopharmaceuticals prepared from Arnica flowers CA Klaas, G Wagner, S Laufer, S Sosa, R Della Loggia, U Bomme, ... Planta medica 68 (05), 385-391, 2002 | 167 | 2002 |
| (6, 7-Diaryldihydropyrrolizin-5-yl) acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase SA Laufer, J Augustin, G Dannhardt, W Kiefer Journal of medicinal chemistry 37 (12), 1894-1897, 1994 | 160 | 1994 |
| COX-3: just another COX or the solitary elusive target of paracetamol? JM Schwab, HJ Schluesener, S Laufer The Lancet 361 (9362), 981-982, 2003 | 154 | 2003 |
| Progress towards a public chemogenomic set for protein kinases and a call for contributions DH Drewry, CI Wells, DM Andrews, R Angell, H Al-Ali, AD Axtman, ... PloS one 12 (8), e0181585, 2017 | 150 | 2017 |
